Matinas BioPharma Holdings, Inc. (MTNB) Earnings History
Net Loss13 years of earnings data (2012–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Matinas BioPharma Holdings, Inc. (MTNB) Earnings Overview
As of June 23, 2026, Matinas BioPharma Holdings, Inc. (MTNB) reported trailing twelve-month net income of -$17M, reflecting +5.7% year-over-year growth. The company earned $-3.22 per diluted share over the past four quarters.
Looking at the long-term picture, MTNB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$116,075 in fiscal 2012.
Matinas BioPharma Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARQT (-$2M net income, -4.3% margin), NKTR (-$158M net income, -297.1% margin), PRAX (-$327M net income), MTNB has comparable earnings metrics. Compare MTNB vs ARQT →
MTNB Earnings vs Peers
Earnings metrics vs comparable public companies
MTNB Historical Earnings Data (2012–2024)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$24M | -5.7% | -$25M | $-4.98 | - | - |
| 2023 | -$23M | -9.3% | -$24M | $-5.28 | -2093.2% | -2168.4% |
| 2022 | -$21M | +9.8% | -$25M | $-3.00 | -658.6% | -771.3% |
| 2021 | -$23M | -3.7% | -$25M | $-5.04 | -70554.5% | -74954.5% |
| 2020 | -$22M | -29.2% | -$24M | $-5.23 | -14177.0% | -15288.4% |
| 2019 | -$17M | -23.4% | -$19M | $-5.37 | -19343.4% | -21067.4% |
| 2018 | -$14M | +9.1% | -$15M | $-7.18 | -11760.4% | -12230.9% |
| 2017 | -$15M | -103.8% | -$17M | $-8.56 | -10345.9% | -11024.6% |
| 2016 | -$8M | +16.8% | -$8M | $-6.59 | - | - |
| 2015 | -$9M | +10.6% | -$10M | $-8.87 | -4697.0% | -5096.0% |
| 2014 | -$10M | -175.3% | -$10M | $-15.93 | - | - |
| 2013 | -$4M | -3098.9% | -$4M | $-5.80 | - | - |
| 2012 | $-116,075 | - | $-116,075 | $-0.58 | - | - |
Download Data
Export MTNB earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MTNB — Frequently Asked Questions
Quick answers to the most common questions about buying MTNB stock.
What is MTNB earnings per share (EPS)?
MTNB trailing twelve-month (TTM) diluted EPS is $-3.22, reflecting +5.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2024 is available in the table on this page.
What is Matinas BioPharma Holdings, Inc.'s net income?
Matinas BioPharma Holdings, Inc. (MTNB) trailing twelve-month net income is $-17M as of 2024. Earnings grew +5.7% year-over-year.
Is MTNB profitable?
MTNB is not currently profitable on a TTM basis, reporting a net loss of $-17M. Net margin is N/A. Investors should monitor for a return to profitability.
What is MTNB's earnings growth rate?
MTNB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2024.
What are MTNB's profit margins?
Matinas BioPharma Holdings, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -180.7%.
Is MTNB growing earnings?
MTNB is growing earnings steadily. YoY EPS growth of +5.7% is consistent with the 5-year CAGR of N/A. TTM net income is $-17M.
What was MTNB's best earnings year?
Matinas BioPharma Holdings, Inc.'s highest annual net income on record is $-116075.00, achieved in fiscal year 2012. Earnings history on this page spans 2012 to 2024 and includes all annual and quarterly figures.
What were MTNB's earnings last quarter?
MTNB's most recent reported quarter was Q3 2025. Net income was $-2M with diluted EPS of $-0.40. For a full breakdown of all quarters, see the quarterly earnings table on this page.